Australia To Fund New Hepatitis C Drugs From March
This article was originally published in Scrip
Three new hepatitis C treatments – Gilead Sciences' Sovaldi (sofosbuvir) and Harvoni (sofosbuvir + ledipasvir) and Bristol-Myers Squibb's Daklinza (daclatasvir) – are to be made available in Australia from March 1 through the Pharmaceutical Benefits Scheme (PBS). No details have been given on the prices of the drugs, although it seems they were listed following price negotiations with manufacturers aimed at making them cost effective.
Register for our free email digests: